Piomic Medical

Chronic wounds are a widespread, growing phenomenon caused by an aging population and an increasing occurrence of diabetes. Wound care is an extremely large burden to healthcare systems, and has a huge impact on patients' health and mental well-being. Direct medical cost, which includes treating wounds 2-3 times per week for months or years, is estimated to amount to up to USD 100 billion annually. The Swiss startup Piomic has developed an already CE-marked medical device that has been proven to promote the healing of chronic wounds that are difficult to treat and cause persistent pain to patients. Piomic’s COMS technology synergistically applies optical and magnetic stimulation externally to a wound. Its efficacy has been demonstrated in a clinical trial which showed a 2.5x accelerated wound healing rate. Piomic solution is the only one designed for home care and is highly cost-effective.
piomic logo 169 color - Verve Ventures portfolio
Founders / Management Jari Kruth, Christopher Hertz, Marc Walter
Sectors Health & Bio, MedTech
Located in Zurich
Co-Investors Swiss Diabetes Venture Fund
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.